No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Beijing Strong Biotechnologies, Inc. operates as a supplier of in-vitro diagnostic (IVD) solutions, encompassing both products and associated services, for markets within the People's Republic of China and globally. The firm's comprehensive product line includes offerings for clinical biochemistry, such as diagnostic reagents and sophisticated automated analyzers. Additionally, it provides coagulation-related items, including necessary reagents and automated analysis instrumentation. Furthermore, its serology division delivers blood type testing cards and advanced automated systems for blood grouping. This enterprise was established in 2001 and has its corporate headquarters situated in Beijing, China.
www.bsbe.com.cnNo one on the platform currently holds 300406.SZ.
No tracked institution reports a position in 300406.SZ as of their last filing.
No one on the platform has traded 300406.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.4% | 10.5% | 17.2% | — | — | — |
| Rev. Growth % | -18.3% | 9.8% | ||||
| Profit Margin % | 14.0% | 25.5% | 29.9% | |||
| Free Cash Flow Margin % | 38.8% | 26.8% | 23.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.4B | +1.4% | $0.69 | $0.69–$0.69 | — | 1 |
| 2027 | $1.6B | +9.6% | $0.84 | $0.84–$0.84 | — | 1 |
| 2028 | $1.7B | +10.9% | $0.97 | $0.97–$0.97 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300406.SZBeijing Strong Biotechnologies, Inc. | $11.12 | -0.80% | $6.5B | — |
| 000597.SZNortheast Pharmaceutical Group Co., Ltd. | $4.61 | -0.22% | $6.6B | — |
| 000650.SZRenhe Pharmacy Co., Ltd. | $5.18 | -0.58% | $7.2B | — |
| 000915.SZShandong Wit Dyne Health Co.,Ltd. | $24.26 | -0.21% | $5.7B | — |
| 002437.SZHarbin Gloria Pharmaceuticals Co., Ltd |
| $3.37 |
| +0.60% |
| $7.5B |
| — |
| 002950.SZAllmed Medical Products Co.,Ltd | $8.39 | -0.59% | $5.3B | — |
| 300206.SZEdan Instruments, Inc. | $10.98 | +0.18% | $6.4B | — |
Source: Financial Modeling Prep · peers by sector/industry